DOCSLIB.ORG

Somerset Job Postings 052421

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Somerset Job Postings 052421 Company City Job Title Job URL South Bound Advantage Solutions Brook Part Time Retail Reset Merchandiser https://nlx.jobsyn.org/22226cffc42b440a9cc870a3d9c2421f159 Advantage Solutions Somerset Part Time Retail Reset Merchandiser https://nlx.jobsyn.org/bf18a1b9b273416e928f55c1179f30dd159 Advantage Solutions Manville Part Time Retail Reset Merchandiser https://nlx.jobsyn.org/a090452465764d0ebb30f014e81cfd96159 Aerie Pharmaceuticals Bedminster Clinical Research Associate https://nlx.jobsyn.org/4bb648d8259b4fcd8c3335eea1bbb8d0159 Aimbridge Hospitality Branchburg Housekeeper https://nlx.jobsyn.org/c30a1022419246588b9801aae1bb8d0a159 House Attendant Full time -Flexible Evening Aimbridge Hospitality Branchburg Hours https://nlx.jobsyn.org/47c18aa3ba664c66acf7330d973b7beb159 Aimbridge Hospitality Branchburg House Attendant https://nlx.jobsyn.org/76cb005ce4d0426185e6eda444f1e317159 Aimbridge Hospitality Branchburg Front Desk Manager OEM https://nlx.jobsyn.org/c627268893374025be42aec72e41d100159 Aimbridge Hospitality Branchburg Complimentary AM Attendant https://nlx.jobsyn.org/dd0bc37ef15240cda04d4767cff64f0e159 Air Liquide USA LLC Somerville Maintenance Technician https://nlx.jobsyn.org/a3a338e6bed6463481fc78bdc8d6ab8e159 Air Liquide USA LLC Somerville Global Controller https://nlx.jobsyn.org/9c0bcaf89ff0429faa5f8b5c909d92f5159 Akorn Operating Company LLC Somerset QA Investigation Specalist II https://nlx.jobsyn.org/403a070289d04889a9b473bb52bbf2ad159 Akorn, Inc Somerset QA Technician I (1st Shift) https://nlx.jobsyn.org/0a8813f06abb46d5b77ea13071432086159 Packaging/ Production Mechanic Akorn, Inc Somerset (Pharmaceutical Manufacturing)i https://nlx.jobsyn.org/79b91cb8da674cceb859c581ca237d62159 Akorn, Inc Somerset Data Integrity and Compliance Manager https://nlx.jobsyn.org/3d69cf02457c4dc39f693178cd95caea159 Allied Universal Somerville Security Guard Construction Site https://nlx.jobsyn.org/d6e435c8cb74467183f7121e6dfc6e55159 Allied Universal Somerset Security Officer Pharmaceutical https://nlx.jobsyn.org/9867bcfdcd1742bfb541f686687d2086159 Allied Universal Somerset Security Officer Gated Community https://nlx.jobsyn.org/2c33aea266a248b1be486033ab5d5129159 Allied Universal Somerset Security Guard Corporate https://nlx.jobsyn.org/ca08e3cd3add429b896a8342f1066415159 Allied Universal Somerset Retail Security Officer https://nlx.jobsyn.org/1b6208a878424e3388cd20dc32c119e9159 Allied Universal Raritan Security Officer Pharmaceutical https://nlx.jobsyn.org/1b715c61421e4e98bf346e7f4125df55159 Allied Universal Raritan Security Guard Corporate https://nlx.jobsyn.org/8555bb249a794461a9fcdfe887a07766159 Allied Universal Manville Security Officer Auction Dealer https://nlx.jobsyn.org/7b7f2bf442be4457800dbeaa25626347159 Allied Universal Hillsborough Security Guard Construction Site https://nlx.jobsyn.org/6506bf0eed8e443c881430fb4c7464f5159 Allied Universal Bridgewater Security Officer Telecommunications https://nlx.jobsyn.org/77df4a12868e4783a588294156e4dd7e159 Allied Universal Bridgewater Security Officer Corporate Headquarters https://nlx.jobsyn.org/9048426372c14ca1987fb0de1bb9376e159 Allied Universal Branchburg Security Officer Telecommunications https://nlx.jobsyn.org/455acb12216444a98ac21abc295e557a159 Allied Universal Branchburg Security Officer Manufacturing https://nlx.jobsyn.org/841d151a549f418ab2b35b3b55d6a070159 Allied Universal Branchburg Security Officer College https://nlx.jobsyn.org/90d31357316d485faf39cc93906914b8159 American Spraytech Somerville Warehouse/Forklift Operator https://nlx.jobsyn.org/2e1e58f3efa046f1a689e1874cf09dc5159 American Spraytech Somerville Truck Driver https://nlx.jobsyn.org/9d08bc57de634a0b87c77cf0a2d79b4a159 American Spraytech Somerville Senior Lab Technician - R&I https://nlx.jobsyn.org/9d8c170d595c4110bc5b755d2b04e5dc159 American Spraytech Somerville Quality Control Lab Technician https://nlx.jobsyn.org/6970bfa947d3402b95a03888a42f5e52159 Amneal Pharmaceuticals Bridgewater Specialty Sales Representative - Austin, TX https://nlx.jobsyn.org/2b95c5f5db12461e8b87665cf998609e159 Amneal Pharmaceuticals Bridgewater Rebate Analyst I https://nlx.jobsyn.org/03923e41c6ad454caa4f783857805f2f159 Amneal Professional Sales Representative - Pharmaceuticals Bridgewater Montgomery, AL https://nlx.jobsyn.org/dae1e0143a25446b99472f8d09e3c340159 Amneal Pharmaceuticals Bridgewater Manager, Rebate Administration https://nlx.jobsyn.org/1c26d31468744cbf9b8c4d4fb378e1a2159 Amneal Pharmaceuticals Bridgewater Driver https://nlx.jobsyn.org/5c5ebc0df6c3443c93e296a13c94ee61159 Amneal Pharmaceuticals LLC (J0P) Somerville Supervisor, Quality Control - 2nd Shift https://nlx.jobsyn.org/9cf3eb829b3148a2aef424c209402025159 Amneal Pharmaceuticals LLC (J0P) Somerville Supervisor, Quality Assurance https://nlx.jobsyn.org/88b7a3e4d7df49d297fd719f0bb21626159 Amneal Pharmaceuticals LLC (J0P) Somerville Scientist III, Quality Control https://nlx.jobsyn.org/00be2a1113ce498f945d35523ec895dc159 Amneal Pharmaceuticals LLC (J0P) Somerville Packaging Operator II - 2nd Shift https://nlx.jobsyn.org/2a9c41e102cd4a079b5496ffd10cab7b159 Amneal Pharmaceuticals LLC (J0P) Somerville Packaging Operator I - 2nd Shift https://nlx.jobsyn.org/51a86bd3545942f2b0de3db8b627d850159 Amneal Pharmaceuticals LLC (J0P) Somerville Packaging Operator I https://nlx.jobsyn.org/87632e79faf14679b70936b37620ee70159 Amneal Pharmaceuticals LLC Intern - Manufacturing Tech Services (J0P) Somerville Operations https://nlx.jobsyn.org/79af0a070dfd4eb99e636bc84defc1b1159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Specialty Sales Representative - Austin, TX https://nlx.jobsyn.org/ed647ea32dee4a00bdbc3825da6dd32f159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Rebate Analyst I https://nlx.jobsyn.org/e1bd5508df21447389cccf5e5f074571159 Amneal Pharmaceuticals LLC Professional Sales Representative - (J0P) Bridgewater Montgomery, AL https://nlx.jobsyn.org/0558309454b6409bb1f4864423f7199d159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Manager, Rebate Administration https://nlx.jobsyn.org/3b7fe6e6c2ef470db771faac4fba50ba159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Executive Assistant https://nlx.jobsyn.org/6dcc8d237b4346c8b57213f9164ed2a9159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Executive Assistant https://nlx.jobsyn.org/c19d0042bf174f7bb38e339882a518e6159 Amneal Pharmaceuticals LLC (J0P) Bridgewater Driver https://nlx.jobsyn.org/34c49b9589644923adb98fdff8b8a686159 Aon Corporation Somerset Time Away & Life Solutions Consultant https://nlx.jobsyn.org/4051987839814dcf8d7ed3f7b825a7b4159 Applied Industrial Technologies Somerset Account Manager(Industrial Sales) https://nlx.jobsyn.org/45bff0bd98594f8ba522d390a04af960159 AquaSafe Pool Management, Inc. Montgomery Summer Lifeguard https://nlx.jobsyn.org/12dc777670ac421a86934535240ebaad159 AquaSafe Pool Management, Inc. Montgomery Summer Lifeguard https://nlx.jobsyn.org/3452eea165a043198702238906df0e3a159 Ashland, LLC Bridgewater Staff Scientist - Mass Spectrometrist https://nlx.jobsyn.org/8b76e3689ed44e249b82d2690a8bb5f4159 Ashland, LLC Bridgewater Analytical Scientist https://nlx.jobsyn.org/bcfcb07dbc6c41808f94191455c4462a159 AT&T Bedminster Technical Sales Consultant 4 https://nlx.jobsyn.org/a43a88cc5d94456f8a98f1d8a2babf29159 AT&T Bedminster Technical Sales Consultant 2 https://nlx.jobsyn.org/3948d68bfc774cccbc83e2f629b1b652159 AT&T Bedminster Specialist-Network Support (Government) https://nlx.jobsyn.org/b4e4b5504a6440bc849fdff9ac518d82159 AT&T Bedminster Software Engineer II https://nlx.jobsyn.org/4eac20de80f643f6a4d61e91a904ebf9159 AT&T Bedminster Senior/Principal - Data Scientist https://nlx.jobsyn.org/b6b8e023aca14024a43ce7535a04bd99159 AT&T Bedminster Senior-Technology Security https://nlx.jobsyn.org/3cfd6fa3c3fb4f1597d7a4f204a3205a159 AT&T Bedminster Senior-Technology Security https://nlx.jobsyn.org/d13f2a898b444f419105362bfe7cafcc159 AT&T Bedminster Senior Enterprise Architect https://nlx.jobsyn.org/ce6fb9a7c0814ed4acf5d5db20ef1bcd159 AT&T Bedminster Senior Client Support Specialist https://nlx.jobsyn.org/38597245f0474e5f8ae07065c1bed95d159 Senior Application Sales Executive - AT&T Bedminster Cybersecurity https://nlx.jobsyn.org/af94d55758f6479c937d75ea2e186cba159 AT&T Bedminster Professional Systems Administrator * https://nlx.jobsyn.org/65d96fcc8869460da8fe7acb7b86048e159 AT&T Bedminster Professional Applications Developer https://nlx.jobsyn.org/4ef7115690644c97a9376f4bb78f6e6a159 AT&T Bedminster Principal Member of Technical Staff https://nlx.jobsyn.org/82064828ef2e4af1a331b1bee2011a04159 Platform Engineer II (Business Intelligence/ AT&T Bedminster ETL) https://nlx.jobsyn.org/bb188e69a35d461fabb05475c91e3907159 Inventive Scientist- Labs Network Analytics AT&T Bedminster & Automation https://nlx.jobsyn.org/92b22e8f2d264db38719d2bcb97843f2159 AT&T Bedminster Director, Engineering Quality https://nlx.jobsyn.org/418e712b6674492e9ffbbc9383563acb159 Client Solutions Executive Integrated AT&T Bedminster Mobility https://nlx.jobsyn.org/b7df8fc9f75a4926a320675fb2c4ef33159 AT&T Bedminster Client Solutions Executive 4 https://nlx.jobsyn.org/7b03f4cb78de4b17a60e613c3f69766d159 AT&T Bedminster Client Solutions Executive 3 Mobility https://nlx.jobsyn.org/0b74e5ca9d914514a1582a5d8a9d6234159 B2B Sales Development Program - 2021 AT&T Bedminster Start Dates https://nlx.jobsyn.org/0bafb40d399c4601a68f72464c252c4f159 AT&T Bedminster Applied Research Scientist https://nlx.jobsyn.org/fc8c3ff8c08442c9921224ad37f94e99159 Avantor, Inc. Raritan Inventory Coordinator https://nlx.jobsyn.org/7281fb061db04516a2d195175db5257b159 Avantor, Inc. Bridgewater
Load more

Recommended publications
  • Symbols Alexian Brothers Health System Index to Nov P
    Volume 19, Index December 2014 Symbols Alexian Brothers Health System Index to Nov p. 2 Health Care M&A News 1-800-CONTACTS Feb p. 18 A&L Goodbody Apr p. 16, July p. 16 All Care Home Health, LLC Feb p. 17 Each company and orga- A Allergan Inc. Feb p. 10, May p. 1, nization discussed in Health May p. 19, Jun p. 15, July p. 3, Care M&A News, from Janu- Abbott Labs July p. 3, Aug p. 17, July p. 10, Sept p. 16, Oct p. 3, ary through December 2014, Dec p. 4 Nov p. 1, Dec p. 4, Dec p. 16, is listed alphabetically here. AbbVie Inc. July p. 3, July p. 16, Dec p. 19 References are typically to Aug p. 9, Oct p. 2, Oct p. 16, Allscripts Feb p. 2, Apr p. 10 the first occurrence of the Nov p. 19, Dec p. 2 AllSpire Health Partners Nov p. 2 company’s or organiza- ABL, Inc. Aug p. 18 All Staffing Services Jan p. 17 tion’s name in the pertinent Acadia Healthcare Company Feb p. 16, Almost Family, Inc. Apr p. 16 issue; further discussion July p. 17, Oct p. 17, Nov p. 17 ALN Medical Management, LLC may follow later in the text Accelera Innovations, Inc. Jan p. 17 Accelrys, Inc. Jan p. 15 Feb p. 8 but is not indicated here. AccessClosure, Inc. May p. 15 Alta Partners Jun p. 16 Achillion Pharmaceuticals July p. 17 Altos Solutions, Inc. Jun p. 15 References are sorted by Actavis (Foshan) Pharmaceuticals Co.
    [Show full text]
  • Preclinical Development & IND Filing: Nuts, Bolts, Best Practices
    “Preclinical Development & IND Filing: Nuts, Bolts, Best Practices and Regulatory Aspects.” Speakers: Amit Kalgutkar (Pfizer), Chandra Prakash (Agios), Sanjeev Thohan (Novartis), Li- Chun Wang (Takeda), Wei Yin (Biogen) Organizers: Sanjeev Thohan and Chandra Prakash Date: 6/29/2017 Time: 8:30 am – 5.00 pm Location: Boston/Cambridge Area: Marriott Kendall Square, 50 Broadway, Cambridge MA 02142 Fees: $175 - Regular (before June 1st, 2017), $225 - Regular (after June 1st, 2017); $125 - Unemployed & Academic; $2000 - Major Sponsorship; $475 - Vendor Show Registration: www.PBSS.org Workshop Description: An investigational new drug application (IND) is an important milestone that marks the entry of a molecule into clinical development. Knowing the objectives, expectations and processes of assembling an IND is a key to not only successful filing, but also a promising clinical development path forward. Often there are cases where too many of our “nice-to-have” studies crowd the package at the expense of critical study needs/issues. This can lead to significant delays in clinical developments with back-and-forth of Q&A sessions both internally and with regulatory agencies. As we have seen, the regulatory landscape is changing as rapidly as the industry innovates into new therapeutic modalities. Therefore, it is critical to keep up to date on regulatory requirements and the industry’s best practices in different aspects of the IND: non- clinical safety, PK, CMC, and clinical plans. In this workshop, our speakers who bring years of experience with multiple successful IND filings, will discuss systematically the preclinical studies required for small molecule IND’s as well as the nuts and bolts of putting together a high–quality IND package.
    [Show full text]
  • Healthcare & Life Sciences Group
    HEALTHCARE & LIFE SCIENCES GROUP 2 1 Healthcare and life sciences clients have long turned to S&C for help succeeding in today’s rapidly changing business environment. Large and mid-size, public and private, throughout their lifecycles, these companies rely on our multi-disciplinary, global team to address their most complex legal and business challenges and reach their strategic goals. Sector expertise: We offer unrivaled OUR CLIENTS GET… knowledge of the healthcare and life sciences industries, our clients’ businesses and the sector-specific competitive pressures bearing down on them. Sullivan & Cromwell’s Healthcare and Life Sciences Group has negotiated complex transactions and resolved high-stakes disputes for almost three decades. Today, it possesses an unparalleled grasp of these sectors and a practical understanding of the commercial realities underlying them. We position our clients to succeed through it all. The Firm represents international clients in the following healthcare sectors: Pharmaceuticals and Life Sciences Medtech Health Insurers Healthcare Services 2 Legal expertise: Clients come to us An integrated, global team: for the high-quality counsel and hands-on We’re a core group of dedicated healthcare representation we offer across multiple advisers across our 13 offices on four legal specialties, to successfully execute continents with a strong track record of their most important deals and resolve the sector’s most significant transactions critical disputes. We can execute any type and litigation matters, supported by all of transaction in any economic climate or the resources of an integrated, global firm. geographic region. Our experience in this We’re grateful to our clients for trusting sector includes: us with their future, and we’ll continue to help them position themselves for growth M&A and success in this exciting and ever- Corporate finance changing industry.
    [Show full text]
  • Stamford Therapeutics Consortium Consortiapedia.Fastercures.Org
    Stamford Therapeutics Consortium consortiapedia.fastercures.org Stamford Therapeutics Consortium consortiapedia.fastercures.org/consortia/stamford-therapeutics-consortium/ Research Areas At a Glance Status: Active Consortium Tool Development Year Launched: 1994 Clinical Trial Initiating Organization: Dr. Paul Dalgin Data-Sharing Enabler Initiator Type: Industry Location: North America DevelopmentProduct Drugs Abstract Stamford Therapeutics Consortium (STC) is a privately owned and operated clinical research site specializing in phase II, III, and IV clinical trials for the pharmaceutical and biotechnology industries. STC has a strong working relationship with a cardiology group, a large multispecialty medical practice, and a team of physicians who serve as sub-investigators for many of its clinical trials. STC maintains a significant presence in research for the treatment of osteoarthritis and rheumatoid arthritis, while continuing to expand its research into new therapeutic areas. Year after year STC's list of specialties grows to accommodate a growing demand and new innovations in healthcare. With over 15 years of clinical trials operations, STC has conducted more than 350 national and multi-national clinical trials. Mission The company’s sole mission is to conduct the highest quality clinical trials so that new, safe, and effective medications can be developed, researched, and approved for a variety of indications and diseases. Stamford Therapeutics Consortium - consortiapedia.fastercures.org Page 1/4 Stamford Therapeutics Consortium consortiapedia.fastercures.org Consortium History The site was launched in 1994 and has contributed to clinical trials research ever since. Structure & Governance The consortium is governed by their president, medical director, founder, and clinical research coordinators. Patent Engagement STC actively recruits patients from all over Fairfield County, CT and Westchester County, NY.
    [Show full text]
  • Bristol-Myers Squibb Company [email protected]
    UNITED STATES SECURITIES A ND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 DIVISION OF CORPORATION FINANCE March 1, 2019 Lisa A. Atkins Bristol-Myers Squibb Company [email protected] Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 Dear Ms. Atkins: This letter is in response to your correspondence dated December 21, 2018 concerning the shareholder proposal (the “Proposal”) submitted to Bristol-Myers Squibb Company (the “Company”) by People for the Ethical Treatment of Animals (the “Proponent”) for inclusion in the Company’s proxy materials for its upcoming annual meeting of security holders. We also have received correspondence from the Proponent dated January 3, 2019. Copies of all of the correspondence on which this response is based will be made available on our website at http://www.sec.gov/divisions/corpfin/ cf-noaction/14a-8.shtml. For your reference, a brief discussion of the Division’s informal procedures regarding shareholder proposals is also available at the same website address. Sincerely, M. Hughes Bates Special Counsel Enclosure cc: Jared Goodman PETA Foundation [email protected] March 1, 2019 Response of the Office of Chief Counsel Division of Corporation Finance Re: Bristol-Myers Squibb Company Incoming letter dated December 21, 2018 The Proposal asks the board to implement a policy that it will not fund, conduct or commission use of the “Forced Swim Test.” There appears to be some basis for your view that the Company may exclude the Proposal under rule 14a-8(i)(7), as relating to the Company’s ordinary business operations. In our view, the Proposal micromanages the Company by seeking to impose specific methods for implementing complex policies.
    [Show full text]
  • Investor Presentation March 19, 2019
    Transaction Update INVESTOR PRESENTATION MARCH 19, 2019 1 Important Information For Investors And Stockholders This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It does not constitute a prospectus or prospectus equivalent document. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the U.S. Securities Act of 1933, as amended. In connection with the proposed transaction between Bristol-Myers Squibb Company (“Bristol-Myers Squibb”) and Celgene Corporation (“Celgene”), on February 1, 2019, Bristol-Myers Squibb filed with the Securities and Exchange Commission (the “SEC”) a registration statement on Form S-4, as amended on February 1, 2019 and February 20, 2019, containing a joint proxy statement of Bristol-Myers Squibb and Celgene that also constitutes a prospectus of Bristol- Myers Squibb. The registration statement was declared effective by the SEC on February 22, 2019, and Bristol-Myers Squibb and Celgene commenced mailing the definitive joint proxy statement/prospectus to stockholders of Bristol-Myers Squibb and Celgene on or about February 22, 2019. INVESTORS AND SECURITY HOLDERS OF BRISTOL-MYERS SQUIBB AND CELGENE ARE URGED TO READ THE DEFINITIVE JOINT PROXY STATEMENT/PROSPECTUS AND OTHER DOCUMENTS FILED OR THAT WILL BE FILED WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY BECAUSE THEY CONTAIN OR WILL CONTAIN IMPORTANT INFORMATION. Investors and security holders will be able to obtain free copies of the registration statement and the definitive joint proxy statement/prospectus and other documents filed with the SEC by Bristol-Myers Squibb or Celgene through the website maintained by the SEC at http://www.sec.gov.
    [Show full text]
  • Healthcare & Life Sciences Industry Update
    Healthcare & Life Sciences Industry Update August 2011 Member FINRA/SIPC www.harriswilliams.com What We’ve Been Reading August 2011 • The biggest story from inside the Beltway over the last month was the battle and eventual deal to raise the U.S. debt ceiling to avoid an impending August 2nd default. The Budget Control Act of 2011 will raise the debt ceiling by $2.1-$2.4 trillion, while reducing spending by approximately $2.1 trillion over the next decade. In an interesting post-deal analysis, Michael Hiltzik of the Los Angeles Times notes that despite the protracted negotiations over a broad spectrum of cost-cutting measures, healthcare was not raised as a primary issue. Some have found this especially concerning, considering the outsized portion of the Federal Budget currently allocated to healthcare spending, which is forecast to rise in the coming years. A recent article in The Economist, entitled “Looking to Uncle Sam” makes this point and goes further to suggest that Centers for Medicare & Medicaid Services (CMS) actuaries may be underestimating future increases in Medicare and Medicaid spending. • One potential reason CMS actuaries may be underestimating the future costs of Medicare and Medicaid relates to healthcare reform’s effect on employee benefits, and specifically, the 2014 switch to subsidized exchange policies. A recent report by McKinsey & Company estimates that approximately 30% of employers will stop offering employer- sponsored insurance (ESI) when this switch is made, as opposed to the 7% estimated by the Congressional Budget Office. An ESI exodus of this magnitude could cause substantial strain on an already robust government healthcare budget.
    [Show full text]
  • Download Agenda
    Break Through Affordability Barriers to Streamline Operational Complexities, Enhance Patient Access and Optimize Stakeholder Collaboration August 17-19, 2021 Elevated Insights Shared From Top Leaders Across the Access and Affordability Landscape Bill Goodson, Savaria B. Harris, Director, Senior Counsel, Patient Assistance, Regulatory Law, EISAI JOHNSON & JOHNSON Tyler Scheid, Debra Autry, Senior Policy Analyst, Medication Access AMERICAN MEDICAL Coordinator, ASSOCIATION HEALTH ALLIANCE FOR THE UNINSURED Viveca Parker, Assistant US Attorney, PLUS! Perspectives from Sanofi, Mallinckrodt DEPARTMENT OF JUSTICE Pharmaceuticals, Acceleron Pharma Inc., and more! INFORMACONNECT.COM/PAP #PAP2021 ABOUT THIS EVENT Now in its 22nd year, Informa Connect’s Patient Assistance and Access Programs convenes leaders from across the assistance, access and affordability field to benchmark on PAP industry standards and break through affordability barriers to streamline operational complexities, enhance patient access and optimize stakeholder collaboration. % 4% Bio/Pharma 57% AUDIENCE SNAPSHOT 5 3% Non-Profit/Foundation 21% 2021 ADVISORY 10% Consulting 10% COMMITTEE: March 2021 % Delegation Breakdown: 21% 57 Health Plan/System 5% Pharmacy/PBMs 4% A sincere thank you to the Hospital/Medical Center/Clinic 3% Advisory Committee Members for their support and guidance in developing the robust program agenda aimed at BENCHMARKING DATA addressing industry’s most pressing challenges. The Top 3 Biggest of surveyed individuals changed the % course of the programs they
    [Show full text]
  • Greater Raritan Labor Insight Analysis
    Greater Raritan 90-Day Labor Insight Analysis • Somerset County • Hunterdon County Greater Raritan Cities With The Most Listings Last 90 days (Nov. 7, 2019 - Feb. 4, 2020) * Due to data coding errors, all Heavy and Tractor-Trailer Truck Driver occupations have been suppressed Bridgewater, NJ 3,368 Franklin, NJ 2,407 Bernards, NJ 2,264 Bound Brook, NJ 1,091 Flemington, NJ 930 Somerville, NJ 865 Warren, NJ 811 Raritan, NJ 706 Bedminster, NJ 621 Readington, NJ 472 Hillsborough, NJ 470 Montgomery, NJ 316 Peapack, NJ 274 Watchung, NJ 261 Clinton, NJ 236 North Plainfield, NJ 187 Lebanon, NJ 172 Bernardsville, NJ 113 Manville, NJ 103 Green Brook, NJ 94 Gladstone, NJ 73 0 1,000 2,000 3,000 4,000 • Source: Burning Glass Technologies Inc., Labor Insight Prepared by New Jersey Department of Labor & Workforce Development – February, 2020 Greater Raritan Industries (4 digit NAICS) With The Most Listings Last 90 days (Nov. 7, 2019 - Feb. 4, 2020) * Due to data coding errors, all Heavy and Tractor-Trailer Truck Driver occupations have been suppressed Pharmaceutical and Medicine Manufacturing 1,206 Wired Telecommunications Carriers 656 General Medical and Surgical Hospitals 584 Insurance Carriers 446 Restaurants and Other Eating Places 297 Business Support Services 273 Scientific Research and Development… 256 Depository Credit Intermediation 227 Health and Personal Care Stores 204 Employment Services 199 Computer Systems Design and Related… 193 Offices of Physicians 178 Building Material and Supplies Dealers 156 Clothing Stores 151 Management, Scientific, and Technical… 142 Traveler Accommodation 139 Software Publishers 129 Architectural, Engineering, and Related… 114 Accounting, Tax Preparation, Bookkeeping,… 105 Investigation and Security Services 103 Home Health Care Services 99 0 500 1,000 1,500 • Source: Burning Glass Technologies Inc., Labor Insight Prepared by New Jersey Department of Labor & Workforce Development – February, 2020 Greater Raritan Employers With The Most Listings Last 90 days (Nov.
    [Show full text]
  • Emmett Cunningham, Jr., M.D., Ph.D., M.P.H
    2019 - Emmett Cunningham, Jr., M.D., Ph.D., M.P.H. Senior Managing Director Blackstone Life Sciences HEATHEGY TEAM CRAIG SIMAK CRAIG SIMAK DANIELLE SILVA MAUREEN LINNEMANN 1200 OIS@AAO 24 Meetings > 1,150 1000 ~ 13,500 Attendees 800 OIS@ASCRS 600 > 650 400 OIS@ASRS 200 > 300 0 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 Registrants 3% 10% OIS@AAO 2019 ( > 1,150) 8% Academia, Government, or Association 41% Adviser, Consultant, or Service Provider Finance/Investment Firm Large Multi-National Corporation Physician/Healthcare Provider 25% Press/Media Start-up/Emerging Growth Company 3% 25 Countries 10% 32 US States Record Number of CDER NME NDA/BLA Approvals in 2018 70 BLA 59 60 NDA 50 45 46 Number 39 41 of 40 35 36 Drugs 30 30 30 27 27 24 26 22 24 21 20 21 22 20 17 18 10 0 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 Source: FDA 1998 - 2018 High Innovation Record Number of • 31 (53%) Orphan CDER NME NDA/BLA Approvals in 2018 • 26 (44%) Priority Review • 16 (27%) Fast Track • 12 (20%) Break Through Designation 59 • 18 (30%) Oncology • 1 (0%) Ophthalmology Cenegermin-bkbj Ophthalmic Solution, (OXERVATE®) Ophthalmic Drugs Streamlined Reporting of Ophthalmology Clinical Group CDER As of January, 2018 Ophthalmology Clinical Group Reported Directly & Independently to Deputy Director Office of New Drugs Peter Stein, MD Five Additional Office of Offices of Drug Antimicrobial Evaluation (ODEs) Products Division of Division of Division of Transplant and Anti-Infective Anti-Viral Ophthalmology Products Products Dr.
    [Show full text]
  • Liver Forum 8 Final Participant List
    Liver Forum 8 Final Participant List Manal Abdelmalek, MD, MPH WG P Merav Baz Hecht * Roberto Calle, MD P Duke University School of Medicine Novo Nordisk Inc. Foundation for the National Institutes of Health Jean-Louis Abitbol, MD, MSC* Pierre Bedossa, MD, PhD Inventiva Pharma University of Paris Diderot Bjorn Carlsson, MD, PhD AstraZeneca Juan Gonzalez Abraldes, MD, MMSc* Cynthia Behling, MD, PhD* University of Alberta University of California, San Diego Santos Carvajal, PhD* Pfizer Inc. Nathalie Adda, MD Martin Benson, BSc, PhD* Enanta Pharmaceuticals, Inc. ICON Clinical Research Laurent Castera, MD, PhD Hôpital Beaujon Guruprasad Aithal, BSc, MBBS, MD, Jerome Bernard, PhD FRCP, PhD DIAFIR SA Naga Chalasani, MD SC WG P University of Nottingham Indiana University School of Medicine Mark Berner-Hansen, MD, DMSc Peter Alfinito, PhD Zealand Pharma Jean Chan, MD WG P Covance Conatus Pharmaceuticals, Inc. Annalisa Berzigotti, MD, PhD SC Alina Allen, MD* Inselspital, University of Bern Edgar Charles, MD, MSc Mayo Clinic Bristol-Myers Squibb Jaime Bosch, MD, PhD, FRCP, Ryan Anderson, MS FAASLD Bentley Cheatham, PhD* Forum for Collaborative Research Inselspital, University of Bern Avolynt, Inc Quentin Anstee, BSc, MBBS, PhD, Pol Boudes, MD, PhD Ying Chen, MD* FRCP P CymaBay Therapeutics, Inc. China Food and Drug Administration Newcastle University Medical School Sherif Boulos, BSc(Hons), MSc, PhD Annie Chen, MD, MPH* Anuli Anyanwu-Ofili* Resonance Health Nimbus Therapeutics Janssen Johan Brag, MS, JD Cheronda Cherry-France, MSN, Puneet Arora,
    [Show full text]
  • Validation of Serum Neurofilament Light Chain As a Biomarker of Parkinson’S Disease Progression
    bioRxiv preprint doi: https://doi.org/10.1101/762237; this version posted December 10, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Validation of Serum Neurofilament Light Chain as a Biomarker of Parkinson’s Disease Progression Brit Mollenhauer1,2†, MD; Mohammed Dakna1, PhD; Tzu-Ying Liu3, PhD; Douglas Galasko4, MD; Tatiana Foroud5, PhD; Henrik Zetterberg6,7,8,9, MD; Sebastian Schade1, MD; Roland G. Gera10, MSc Wenting Wang3, PhD, Feng Gao3, PhD; Niels Kruse11, PhD; Mark Frasier12, PhD; Lana M. Chahine13, MD; Christopher S. Coffey,14 PhD; Andrew B. Singleton,15 PhD; Tanya Simuni,16 MD; Daniel Weintraub,17 MD; John Seibyl,18 MD; Arthur W. Toga,19 PhD; Caroline M. Tanner,20 MD, PhD; Karl Kieburtz,21 MD; Kenneth Marek12,18, MD; Andrew Siderowf17, MD; Jesse M. Cedarbaum22 MD; Samantha J. Hutten12, PhD; Claudia Trenkwalder2*, MD; Danielle Graham23*, PhD *both last authors contributed equally 1 Department of Neurology, University Medical Center Goettingen, Germany: [email protected]; [email protected]; [email protected] 2 Paracelsus-Elena Klinik, Kassel, Germany, [email protected] 3 Biostatistics, Biogen, Cambridge MA, USA; [email protected]; [email protected]; [email protected] 4 Department of Neurosciences, University of California, San Diego, San Diego, CA, USA: [email protected] 5 Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN, USA; [email protected] 6 Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Gothenburg, Sweden.
    [Show full text]